# Clinical and Experimental Therapeutics

> **NIH NIH P30** · UNIVERSITY OF CHICAGO · 2021 · $37,040

## Abstract

ABSTRACT
The Clinical and Experimental Therapeutics (CET) Program is a cohesive, integrated group of 51 members
representing nine different Departments. The overall goal of the Program is to foster interaction between basic
and clinical investigators to develop innovative therapies for cancer patients. As the major clinical and
translational arm of the UCCCC, the Program interfaces with all of the other Programs to seamlessly integrate
fundamental cancer research with clinical care and clinical research objectives. The two co-leaders, M. Eileen
Dolan, PhD, a laboratory-based scientist with experience in preclinical and translational studies, and Walter
Stadler, MD, a medical oncologist with expertise in clinical trials and clinical drug development, have
complementary expertise, and work well together to promote the goals of the CET Program. They jointly
address Program-specific issues, including membership, funding, and scientific direction. Dr. Dolan is co-PI of
a T32 Clinical Therapeutics training grant and Dr. Stadler is co-PI of an oncology Paul Calabresi K12 grant;
therefore, they are also well integrated into the training and mentorship of fellows and junior faculty. Program
members place an emphasis on translational and clinical research, as well as lead studies conducted by
national cooperative groups to facilitate the development of new therapies for hematologic malignancies and
solid tumors. The Program has a long-standing interest in all phases of clinical drug development from
preclinical to early-phase trials to cooperative group led Phase III trials with a strong focus on
pharmacogenomics and pharmacology. The specific scientific aims of the CET Program are to:
1) Pursue a broad Program of pharmacogenomic, molecular target, and biomarker research in the preclinical
and clinical settings as well as to translate the findings into clinical practice; 2) Foster interactions between
basic and clinical investigators that will result in innovative and effective therapies; 3) Integrate new drugs and
immunotherapeutics into the development of multimodality therapies for patients with hematologic
malignancies and advanced solid tumors; and 4) Train the next generation of leaders in clinical and
translational research through formal mentoring and career development efforts. These scientific goals are
achieved through programmatic efforts emphasizing three themes: pharmacogenomics, molecular targets, and
biomarkers through preclinical and clinical studies. Program members are supported by $21,333,004 in total
funding (DC), with $7,712,492 in peer-reviewed funding ($5,380,171 from NCI), and $13,620,512 in non-peer-
reviewed support. For the 2013-2016 period, Program members have 888 peer-reviewed publications, with
20% interprogrammatic, 28% intraprogrammatic, and 9% both intra- and interprogrammatic.

## Key facts

- **NIH application ID:** 10162525
- **Project number:** 5P30CA014599-46
- **Recipient organization:** UNIVERSITY OF CHICAGO
- **Principal Investigator:** Mary Eileen Dolan
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $37,040
- **Award type:** 5
- **Project period:** 1997-09-01 → 2023-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10162525

## Citation

> US National Institutes of Health, RePORTER application 10162525, Clinical and Experimental Therapeutics (5P30CA014599-46). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10162525. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*